ImmuCell Reports 28.4% Revenue Growth in Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy ICCC?
Source: NASDAQ.COM
- Strong Sales Performance: ImmuCell Corporation reported preliminary net sales of $10.4 million for Q1 2026, reflecting a 28.4% increase from $8.1 million in the same quarter last year, indicating robust performance in the animal health biologics sector.
- Tri-Shield Product Growth: Sales of the Tri-Shield product surged by 38.5% to $7.9 million, primarily driven by seasonal demand in the cow-calf segment, which further solidifies the company's market position in the industry.
- Strategic Product Line: ImmuCell's flagship product line, First Defence, targets the treatment of scours, a prevalent disease among neonatal calves, effectively improving calf survivability and health, which is crucial for the company's market relevance.
- Future Outlook: The company anticipates a shift in demand towards year-round dairy customers in the second and third quarters, showcasing the adaptability and growth potential of its products, and plans to host a conference call on May 15, 2026, to discuss unaudited financial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCC
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmuCell Appoints New Board Members to Enhance Strategy
- New Board Appointments: ImmuCell has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, aiming to leverage their extensive experience in animal health to enhance the company's strategic capabilities, which is expected to drive innovation and technology development.
- Formation of Strategy and Technology Committee: The newly established Strategy and Technology Committee will be chaired by Guillemette, focusing on supporting management's efforts to improve production efficiency and expand capacity, thereby driving innovation growth for the First Defense® product line.
- Increased Independent Board Representation: The board will consist of seven members, with six being independent, a structural change that not only enhances corporate governance but also provides stronger support for future mergers and strategic decisions.
- Executive Retirements and Successions: Bryan Gathagan and other non-independent board members will retire on April 15, 2026, ensuring the independence and professionalism of corporate governance while continuing to support daily operations for a smooth transition.
See More
ImmuCell Q1 Sales Surge 28.4% Driven by Tri-Shield Demand
- Total Sales Growth: ImmuCell's Q1 total product sales reached $10.4 million, reflecting a 28.4% increase compared to the same period in 2025, indicating a significant performance boost driven by strong market demand.
- Domestic Sales Performance: Domestic sales in 2026 amounted to $9.7 million, a 35.7% increase from 2025, demonstrating the company's sustained competitiveness in the domestic market and further solidifying its market position.
- International Sales Challenges: Despite robust domestic sales, international sales in 2026 were only $0.6 million, a 30.2% decline from 2025, highlighting challenges in the international market that could impact overall growth potential moving forward.
- Product Line Performance: Tri-Shield sales reached $7.9 million, up 38.5%, while Dual Force and other products generated $2.5 million in sales, a 4.4% increase, showcasing strong demand for Tri-Shield as a key driver of overall sales growth.
See More
ImmuCell Reports 28.4% Revenue Growth in Q1 2026
- Strong Sales Performance: ImmuCell Corporation reported preliminary net sales of $10.4 million for Q1 2026, reflecting a 28.4% increase from $8.1 million in the same quarter last year, indicating robust performance in the animal health biologics sector.
- Tri-Shield Product Growth: Sales of the Tri-Shield product surged by 38.5% to $7.9 million, primarily driven by seasonal demand in the cow-calf segment, which further solidifies the company's market position in the industry.
- Strategic Product Line: ImmuCell's flagship product line, First Defence, targets the treatment of scours, a prevalent disease among neonatal calves, effectively improving calf survivability and health, which is crucial for the company's market relevance.
- Future Outlook: The company anticipates a shift in demand towards year-round dairy customers in the second and third quarters, showcasing the adaptability and growth potential of its products, and plans to host a conference call on May 15, 2026, to discuss unaudited financial results.
See More
ImmuCell Reports 28.4% Sales Growth in Q1 2026
- Strong Sales Performance: ImmuCell reported $10.4 million in sales for Q1 2026, reflecting a 28.4% year-over-year increase, indicating robust overall growth, particularly in the domestic market.
- Domestic Market Drive: Domestic sales reached $9.7 million, up 35.7%, primarily driven by strong demand for the Tri-Shield product, showcasing the company's successful strategy in the cow-calf segment.
- International Market Challenges: Despite overall sales growth, international sales fell to $0.6 million, down 30.2%, indicating challenges in the global market that the company needs to address to improve international performance.
- Team Expansion to Support Growth: To bolster growth in Q2 and Q3 2026, the company appointed a new international leader and two domestic field sales managers, aiming to enhance market competitiveness and drive sales growth.
See More
ImmuCell Corporation Q4 2025 Earnings Call Highlights
- Sales Performance: ImmuCell reported product sales of $7.6 million for Q4 2025, a slight decrease of 1.6% compared to Q4 2024, yet domestic sales grew by 8.7% to $7 million, indicating strong performance in the domestic market despite international sales declining to about $600,000 due to order timing issues.
- Margin Improvement: The gross margin for Q4 2025 increased to 38%, up from 37% in Q4 2024, while the full-year gross margin rose from 30% to 41%, demonstrating significant progress in cost control and pricing strategies that enhance profitability.
- Strategic Shift: Management announced a pivot from Re-Tain manufacturing to focus on the First Defense product line, with plans to increase annual production capacity from 4.6 million units to between 5 million and 6 million units through operational enhancements, reflecting confidence in future growth and market demand.
- Financial Health: The company reported a net loss of $1 million for 2025, an improvement from the previous year, with basic net loss per share decreasing from $0.26 to $0.12, while cash on hand stood at $3.8 million and working capital increased to $13 million, indicating robust financial management.
See More
ImmuCell Reports Q4 2025 Financial Results
- Financial Overview: ImmuCell reported a GAAP EPS of -$0.31 for Q4 2025, indicating challenges in profitability that reflect ongoing market pressures and cost management issues.
- Revenue Decline: The company's revenue for the fourth quarter was $7.62 million, a 1.7% year-over-year decrease, suggesting weak sales growth in a competitive market environment, which may impact future investor confidence.
- Market Reaction: Due to the poor financial performance, investors are adopting a cautious outlook on ImmuCell's prospects, potentially leading to stock price volatility that could affect the company's capital-raising capabilities.
- Future Outlook: ImmuCell needs to implement effective strategic measures to improve its financial condition in order to address market challenges and restore investor confidence, ensuring sustainable growth.
See More
ImmuCell Appoints New Board Members to Enhance Strategy
- New Board Appointments: ImmuCell has appointed Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, aiming to leverage their extensive experience in animal health to enhance the company's strategic capabilities, which is expected to drive innovation and technology development.
- Formation of Strategy and Technology Committee: The newly established Strategy and Technology Committee will be chaired by Guillemette, focusing on supporting management's efforts to improve production efficiency and expand capacity, thereby driving innovation growth for the First Defense® product line.
- Increased Independent Board Representation: The board will consist of seven members, with six being independent, a structural change that not only enhances corporate governance but also provides stronger support for future mergers and strategic decisions.
- Executive Retirements and Successions: Bryan Gathagan and other non-independent board members will retire on April 15, 2026, ensuring the independence and professionalism of corporate governance while continuing to support daily operations for a smooth transition.
See More
ImmuCell Q1 Sales Surge 28.4% Driven by Tri-Shield Demand
- Total Sales Growth: ImmuCell's Q1 total product sales reached $10.4 million, reflecting a 28.4% increase compared to the same period in 2025, indicating a significant performance boost driven by strong market demand.
- Domestic Sales Performance: Domestic sales in 2026 amounted to $9.7 million, a 35.7% increase from 2025, demonstrating the company's sustained competitiveness in the domestic market and further solidifying its market position.
- International Sales Challenges: Despite robust domestic sales, international sales in 2026 were only $0.6 million, a 30.2% decline from 2025, highlighting challenges in the international market that could impact overall growth potential moving forward.
- Product Line Performance: Tri-Shield sales reached $7.9 million, up 38.5%, while Dual Force and other products generated $2.5 million in sales, a 4.4% increase, showcasing strong demand for Tri-Shield as a key driver of overall sales growth.
See More
ImmuCell Reports 28.4% Revenue Growth in Q1 2026
- Strong Sales Performance: ImmuCell Corporation reported preliminary net sales of $10.4 million for Q1 2026, reflecting a 28.4% increase from $8.1 million in the same quarter last year, indicating robust performance in the animal health biologics sector.
- Tri-Shield Product Growth: Sales of the Tri-Shield product surged by 38.5% to $7.9 million, primarily driven by seasonal demand in the cow-calf segment, which further solidifies the company's market position in the industry.
- Strategic Product Line: ImmuCell's flagship product line, First Defence, targets the treatment of scours, a prevalent disease among neonatal calves, effectively improving calf survivability and health, which is crucial for the company's market relevance.
- Future Outlook: The company anticipates a shift in demand towards year-round dairy customers in the second and third quarters, showcasing the adaptability and growth potential of its products, and plans to host a conference call on May 15, 2026, to discuss unaudited financial results.
See More
ImmuCell Reports 28.4% Sales Growth in Q1 2026
- Strong Sales Performance: ImmuCell reported $10.4 million in sales for Q1 2026, reflecting a 28.4% year-over-year increase, indicating robust overall growth, particularly in the domestic market.
- Domestic Market Drive: Domestic sales reached $9.7 million, up 35.7%, primarily driven by strong demand for the Tri-Shield product, showcasing the company's successful strategy in the cow-calf segment.
- International Market Challenges: Despite overall sales growth, international sales fell to $0.6 million, down 30.2%, indicating challenges in the global market that the company needs to address to improve international performance.
- Team Expansion to Support Growth: To bolster growth in Q2 and Q3 2026, the company appointed a new international leader and two domestic field sales managers, aiming to enhance market competitiveness and drive sales growth.
See More
ImmuCell Corporation Q4 2025 Earnings Call Highlights
- Sales Performance: ImmuCell reported product sales of $7.6 million for Q4 2025, a slight decrease of 1.6% compared to Q4 2024, yet domestic sales grew by 8.7% to $7 million, indicating strong performance in the domestic market despite international sales declining to about $600,000 due to order timing issues.
- Margin Improvement: The gross margin for Q4 2025 increased to 38%, up from 37% in Q4 2024, while the full-year gross margin rose from 30% to 41%, demonstrating significant progress in cost control and pricing strategies that enhance profitability.
- Strategic Shift: Management announced a pivot from Re-Tain manufacturing to focus on the First Defense product line, with plans to increase annual production capacity from 4.6 million units to between 5 million and 6 million units through operational enhancements, reflecting confidence in future growth and market demand.
- Financial Health: The company reported a net loss of $1 million for 2025, an improvement from the previous year, with basic net loss per share decreasing from $0.26 to $0.12, while cash on hand stood at $3.8 million and working capital increased to $13 million, indicating robust financial management.
See More
ImmuCell Reports Q4 2025 Financial Results
- Financial Overview: ImmuCell reported a GAAP EPS of -$0.31 for Q4 2025, indicating challenges in profitability that reflect ongoing market pressures and cost management issues.
- Revenue Decline: The company's revenue for the fourth quarter was $7.62 million, a 1.7% year-over-year decrease, suggesting weak sales growth in a competitive market environment, which may impact future investor confidence.
- Market Reaction: Due to the poor financial performance, investors are adopting a cautious outlook on ImmuCell's prospects, potentially leading to stock price volatility that could affect the company's capital-raising capabilities.
- Future Outlook: ImmuCell needs to implement effective strategic measures to improve its financial condition in order to address market challenges and restore investor confidence, ensuring sustainable growth.
See More
